Greenline Wealth Management’s Guardant Health GH Stock Holding History

Greenline Wealth Management’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-25	Closed	-$2.56K	–	264
2025 Q4	$2.56K	Buy	+25	New	+$2.24K	﹤0.01%	452

Other funds holding GH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Greenline Wealth Management's GH Position: Q1 2026 in Review

Greenline Wealth Management sold out of Guardant Health (GH) in Q1 2026, closing a stake of 25 shares — an estimated $2.56K sold.

Greenline Wealth Management first reported a position in GH in Q4 2025 and held it in 1 quarter. The position peaked at $2.56K in Q4 2025. 486 funds tracked by Wall St. Rank hold GH as of Q1 2026.

Greenline Wealth Management reported no remaining Guardant Health position as of Q1 2026 after selling out during the quarter.
Greenline Wealth Management sold 25 Guardant Health shares in Q1 2026, an estimated $2.56K.
Greenline Wealth Management first reported a position in Guardant Health in Q4 2025 and held it in 1 quarter.
Greenline Wealth Management's Guardant Health position peaked at $2.56K in Q4 2025.
486 funds tracked by Wall St. Rank held Guardant Health as of Q1 2026.

Based on Greenline Wealth Management's 13F filing for Q1 2026, filed 14 May 2026.